Poststreptococcal Glomerulonephritis

Back

Practice Essentials

Acute glomerulonephritis following streptococcal infection is characterized by the sudden appearance of hematuria, proteinuria, red blood cell casts in the urine, edema, and hypertension with or without oliguria.[1, 2] (See the image below.) Poststreptococcal glomerulonephritis was first recognized as a complication of the convalescence period of scarlet fever in the 18th century.[3] A link between hemolytic streptococci and acute glomerulonephritis was recognized in the 20th century.



View Image

Kidney biopsy from a 7-year-old child with acute poststreptococcal glomerulonephritis. Periodic acid–Schiff stain (at 40x) shows the intracapillary an....

Although the incidence of poststreptococcal glomerulonephritis has declined in the United States, it continues to have high incidence in other parts of the world, especially in areas with tropical climates where skin infections are common.[4, 5]

The workup in patients with suspected acute poststreptococcal glomerulonephritis includes tests to provide evidence of preceding streptococcal infection, renal function studies, and serologic studies (see Workup). The major goal of treatment is to control edema and blood pressure (see Treatment and Medication).

See also Acute Poststreptococcal Glomerulonephritis, Acute Glomerulonephritis, and Emergent Management of Acute Glomerulonephritis.

Pathophysiology

Poststreptococcal glomerulonephritis follows infection with only certain strains of streptococci, designated as nephritogenic. The offending organisms are virtually always group A streptococci. Acute poststreptococcal glomerulonephritis (APSGN) follows pyodermatitis with group A streptococci M protein types 47, 49, 55, 2, 60, and 57 and throat infection with streptococci M types 1, 2, 4, 3, 25, 49, and 12.

Many morphologic, clinical, and serologic features suggest that APSGN is an immune complex disorder in which an immune complex containing a streptococcal antigen is deposited in the affected glomeruli. The size of glomerular basement membrane (GBM) pores and the molecular size of the streptococcus-Ig complex are also important determinants. The molecular size of the streptococcus-Ig complex is about 15 nm (10 nm for streptococcus group A and 5 nm for immunoglobulin). The GBM pore sizes in children and adults are 2-3 nm and 4-4.5 nm, respectively. Therefore, the immune complex molecule can be more easily rodded into the glomerulus in children than in adults and, thus, may explain the higher frequency of APSGN in children than in adults.

Stamatiades et al determined that in PSGN and other type III hypersensitivity reactions, vascular endothelial cells in the kidney actively transport circulating immune complexes from the capillaries to the peritubular interstitial space, where they are detected and scavenged by resident macrophages. Uptake of the immune complexes by the resident macrophages triggers the release of pro-inflammatory cytokines, which in turn results in recruitment of monocytes and neutrophils into the kidney from the circulation.[6]

Two antigens isolated from nephritogenic streptococci are commonly implicated in APSGN: streptococcal pyrogenic exotoxin B (SPEB) and nephritis-associated plasmin receptor (NAPlr).[7, 8] Both SPEB and NAPlr bind plasmin, protecting it from physiological inhibitors, and thus could cause chemotaxis of inflammatory cells and degradation of glomerular basement membranes. Both can be found in the glomeruli of APSGN tissues[8] .

In addition to streptococcal antigens, rheumatoid factor, cryoglobulins, and antineutrophil cytoplasmic serum antibodies are present in some of these patients. The pathogenic significance of this autoimmune response is not defined.

There are also host susceptibility factors. In one study, HLA-DRB1*03011 was reported to be found at a significantly higher frequency in 32 unrelated patients with APSGN as compared to 380 healthy individuals.[9]

Epidemiology

Frequency

United States

The incidence of clinically detectable glomerulonephritis during an epidemic is up to 10% of children with pharyngitis and 25% of children with impetigo. One study reported a change in the epidemiology of APSGN and found that pharyngitis has replaced impetigo as the predominant cause of APSGN.[10]

International

APSGN can occur sporadically or epidemically. The incidence seems to be decreasing in the United States and Europe, but sporadic cases of the disease continue to be reported from all over the world. The prevalence of nephritis varies considerably among persons with sporadic infections with nephritogenic streptococci. The reason for this variability is not known.

A systematic review by Jackson et al demonstrated significant variation in the global incidence of APSGN, with the highest incidence of 239 per 10,000 in Australian Aborigines and lowest incidence of 0.04 in 100,000 in an Italian study of people younger than 60 years.[11]

Epidemic poststreptococcal glomerulonephritis occurs mainly in developing countries in areas such as Africa, the West Indies, and the Middle East. Reasons for this changing epidemiology relate to the nutritional status of the community, the more liberal use of antibiotic prophylaxis, and possibly the change in the nephritogenic potential of streptococci. Among epidemic infections with nephritogenic streptococci, the apparent clinical attack rate is 10-12%.[4, 5]

Mortality/Morbidity

Early death is extremely rare in children (< 1%) but is significantly more common in adults (25%). This is secondary to congestive heart failure and azotemia. Congestive heart failure is more common in adults (43%) than in children (< 5%). Nephrotic-range proteinuria is also more common in adults (20%) than in children (4-10%). Approximately 83% of adults have azotemia, compared with 25-40% of children.

Six cohort studies report case fatality rates from APSGN, with three revealing a case fatality rate of 0%, two studies from India reporting a case fatality rate of 1.4% and 2%, and one study from Turkey reporting a case fatality rate of 0.08%.[11]

The long-term prognosis of children with APSGN has been the subject of several studies. Pooled data of studies published prior to 2000 with 5- to 18-year follow-up indicate abnormal urinalysis in 17.4%, proteinuria in 13.8%, hypertension in 13.8%, and azotemia in 1.3%.[12] A study from Australia demonstrated that APSGN can add to the burden of chronic kidney disease.[13]

Race

No racial predilection is recognized.

Sex

Clinical cases of APSGN are twice as common in males than in females. If subclinical disease is considered, both sexes are affected equally. The familial incidence rate is nearly 40%, but no genetic marker has been identified.

Age

This condition typically affects children aged 2-12 years. A large series reported that 5% are younger than 2 years and 10% are older than 40 years.

History

A history suggestive of preceding streptococcal infection may include a preceding infective episode such as pharyngitis, tonsillitis, or pyoderma. This is the sine qua non for the diagnosis of acute poststreptococcal glomerulonephritis (APSGN).

A latent period always occurs between the streptococcal infection and the onset of signs and symptoms of acute glomerulonephritis. In general, the latent period is 1-2 weeks after a throat infection and 3-6 weeks after a skin infection.[14] The onset of signs and symptoms at the same time as pharyngitis (also called synpharyngitic nephritis) is more likely to be immunoglobulin A (IgA) nephropathy rather than APSGN.

Dark urine (brown-, tea-, or cola-colored) is often the first clinical manifestation of APSGN. Dark urine is caused by hemolysis of red blood cells that have penetrated the glomerular basement membrane and have passed into the tubular system.

Periorbital edema is typical. The onset of puffiness of the face or eyelids is sudden. It is usually prominent upon awakening and, if the patient is active, tends to subside at the end of the day.

In some cases, generalized edema and other features of circulatory congestion, such as dyspnea, may be present. Edema is a result of a defect in renal excretion of salt and water. The severity of edema is often disproportionate to the degree of renal impairment.

Nonspecific symptoms of APSGN can include general malaise, weakness, and anorexia and are present in 50% of patients. Approximately 15% of patients complain of nausea and vomiting.

Unusual presentations of complicated APSGN include the following:

Physical

Acute nephritic syndrome is the most frequent presentation of APSGN. Its manifestations are edema, hematuria, and hypertension, with or without oliguria. Hematuria is present in all cases, and is gross in 30% of cases. Approximately 95% of clinical cases have at least two manifestations, and 40% have the full-blown acute nephritic syndrome.

Edema

Edema is present in 80-90% of cases, and it is the presenting complaint in 60% of cases. Compromised intraglomerular blood flow due to glomerular hypercellularity results in progressive encroachment on the cross-sectional area of the glomerular capillaries. This leads to reduced blood flow that manifests as low fractional excretion of sodium and concentrated urine. This salt and water retention leads to edema.

Hypertension

Hypertension occurs in 60-80% of cases and is more common in elderly individuals. In 50% of cases, the hypertension can be severe; however, more often it is transient, with normalization of blood pressure upon restoration of the glomerular filtration rate, loss of edema, and normalization of plasma volume. If hypertension persists, it is more indicative of the progression to a more chronic stage or that the disease is not poststreptococcal glomerulonephritis.

Hypertension is thought to be the result of excessive salt and water retention. Despite excessive sodium retention, the plasma levels of atrial natriuretic peptide are increased. In this condition, this suggests that the kidneys are unresponsive to atrial natriuretic peptide.

Plasma renin activity is usually low, and studies by Parra et al have shown that an inhibition of angiotensin-converting enzyme could be an effective short-term treatment for this low-renin hypertension.[20]

Hypertensive encephalopathy occurs in no more than 5-10% of patients. Usually, clinical improvement occurs without any neurological sequelae.

Oliguria

Oliguria is present in 10-50% of cases. In 15% of cases, urine output is less than 200 mL. Oliguria is indicative of the severe crescentic form of the disease. It is often transient, with diuresis occurring within 1-2 weeks.

Left ventricular dysfunction

Left ventricular dysfunction with or without hypertension or pericardial effusion may be present during the acute congestive and convalescent phases.

In rare cases, persons with APSGN can show signs of pulmonary hemorrhage.

Causes

Acute poststreptococcal glomerulonephritis (APSGN) follows infection with only certain strains of streptococci designated as nephritogenic. The offending organisms are virtually always group A streptococci. APSGN follows pyodermatitis with streptococci M types 47, 49, 55, 2, 60, and 57 and throat infection with streptococci M types 1, 2, 4, 3, 25, 49, and 12.

Laboratory Studies

Laboratory studies in acute poststreptococcal glomerulonephritis (APSGN) include tests to provide evidence of preceding streptococcal infection, renal function studies, and serologic studies.

Evidence of preceding streptococcal infection can be determined as follows:

Renal function studies

Elevated blood urea nitrogen (BUN) and serum creatinine values reflect the decrease in the glomerular filtration rate that occurs in the acute phase. The elevations are usually transient.Their failure to normalize within several weeks or months indicates that the patient may not have a true APSGN and suggests seeking an alternative diagnosis. Patients who have the crescentic form of glomerulonephritis have rapid deterioration and, often, incomplete recovery of renal function.

Serology

Serologic findings are as follows:

Urinalysis

Findings are as follows:

Other studies

In a study of 28 pediatric patients with APSGN, Taskesen et al found that on clinic admission, the plasma levels of NT-proBNP (an N-terminal peptide left over when the prohormone for brain natriuretic peptide [proBNP] is cleaved to produce active BNP) were higher in these patients than in the 26 healthy children making up the control group.[23] Moreover, the NT-proBNP levels were significantly higher in six patients with APSGN who were found to have left ventricular dysfunction than they were in the patients with APSGN in whom no ventricular dysfunction was diagnosed. The authors suggested that in some patients with APSGN, determination of NT-proBNP levels may prove helpful in the assessment of left ventricular volume overload and cardiac function.

Imaging Studies

Imaging study results may include the following:

Histologic Findings

Pathologic findings of changes in gross appearance findings are as follows:

Light microscopy findings are as follows:

Immunofluorescence findings (see the image below) are as follows:



View Image

Kidney biopsy from a 7-year-old child with acute poststreptococcal glomerulonephritis. Immunofluorescence (C3) shows a granular capillary and mesangia....

Electron microscopy findings are as follows:



View Image

Kidney biopsy from a 7-year-old child with acute poststreptococcal glomerulonephritis. Electron microscopy image shows rare large subepithelial deposi....

Renal Biopsy

Atypical features in the early phase of APSGN that suggest the need for renal biopsy include the following:

Atypical features in the recovery phase that mandate a renal biopsy include the following:

Medical Care

Symptomatic therapy is recommended for patients with acute poststreptococcal glomerulonephritis (APSGN), and it should be based on the clinical severity of the illness. The major goal is to control edema and blood pressure. Those sequelae are most likely to arise in the first 7 to 10 days of APSGN.[14]

During the acute phase of the disease, restrict salt and water. If significant edema or hypertension develops, administer diuretics. Loop diuretics increase urinary output and consequently improve cardiovascular congestion and hypertension.

For hypertension not controlled by diuretics, usually calcium channel blockers, angiotensin-converting enzyme inhibitors (ACEIs), or angiotensin receptor blockers (ARBs) are useful, although ACEIs and ARBs carry the risk of hyperkalemia and temporarily impairing recovery of renal function.[14] For malignant hypertension, intravenous nitroprusside or other parenteral agents are used.

Other features of therapy are as follows:

A renal biopsy is indicated for patients with rapidly progressive renal failure. If the biopsy findings show evidence of crescentic glomerulonephritis with more than 30% of the glomeruli involved, a short course of intravenous pulse steroid therapy is recommended (500 mg to 1 g/1.73 m2 of methylprednisone qd for 3-5 d). However, no controlled clinical trials have evaluated such therapy. Long-term treatment with steroids or immunosuppressives is not recommended.

Specific therapy for streptococcal infection is an important part of the therapeutic regimen. Throat cultures should be performed on patients, family members, and close personal contacts, and treatment should be provided for all patients found to be infected. Treat with oral penicillin G (250 mg qid for 7-10 d) or with erythromycin (250 mg qid for 7-10 d) for patients allergic to penicillin. This helps prevent nephritis in carriers and helps prevent the spread of nephritogenic strains to others.

Patients with skin infections must practice good personal hygiene. This is essential.

During epidemics, recommend that high-risk individuals, including close contacts and family members, receive empirical prophylactic treatment.

Consultations

See the list below:

Diet and Activity

Dietary measures are as follows:

Restricting physical activity is appropriate in the first few days of the illness but is not necessary once the patient feels well.

Medication Summary

Therapy for patients with acute poststreptococcal glomerulonephritis is symptomatic in nature and depends on the clinical severity of the illness. The major aims are to control the edema and blood pressure.

During the acute phase of the disease, salt and water should be restricted. If significant edema or hypertension develops, diuretics should be administered. Loop diuretics increase urinary output and consequently improve cardiovascular congestion and hypertension.

For hypertension not controlled by diuretics, calcium channel blockers or angiotensin-converting enzyme inhibitors are generally useful. For malignant hypertension, intravenous nitroprusside or other parenteral agents are used.

The indications for dialysis include life-threatening hyperkalemia and clinical manifestations of uremia. Steroids, immunosuppressive agents, and plasmapheresis are not generally indicated. In patients with rapidly progressive renal failure, a renal biopsy is indicated. If the biopsy findings show evidence of crescentic glomerulonephritis with more than 30% of the glomeruli involved, a short course of intravenous pulse steroid therapy is recommended (500 mg to 1 g/1.73 m2 of methylprednisone qd for 3-5 d). However, no controlled clinical trials have evaluated such therapy. Long-term treatment with steroids or immunosuppressives is not recommended.

Furosemide (Lasix)

Clinical Context:  Increases excretion of water by interfering with chloride-binding cotransport system, which, in turn, inhibits sodium and chloride reabsorption in ascending loop of Henle and distal renal tubule. Dose must be individualized to patient. Depending on response, administer at increments of 20-40 mg, no sooner than 6-8 h after the previous dose, until desired diuresis occurs. When treating infants, titrate with increments of 1 mg/kg/dose until a satisfactory effect is achieved.

Class Summary

Used to control edema and circulatory congestion.

Amlodipine (Norvasc)

Clinical Context:  Relaxes coronary smooth muscle and produces coronary vasodilation, which, in turn, improves myocardial oxygen delivery. Benefits nonpregnant patients with systolic dysfunction, hypertension, or arrhythmias. Can be used during pregnancy if clinically indicated.

Class Summary

In specialized conducting and automatic cells in the heart, calcium is involved in the generation of the action potential. Calcium channel blockers inhibit movement of calcium ions across the cell membrane, depressing both impulse formation (automaticity) and conduction velocity.

Captopril (Capoten)

Clinical Context:  Prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, resulting in lower aldosterone secretion.

Enalapril (Vasotec)

Clinical Context:  Competitive inhibitor of angiotensin-converting enzyme. Reduces angiotensin II levels, decreasing aldosterone secretion. Clinical response usually observed within 15 min of administration.

Class Summary

Decrease aldosterone secretion.

Nitroprusside (Nitropress)

Clinical Context:  Produces vasodilation and increases inotropic activity of heart. At higher dosages, may exacerbate myocardial ischemia by increasing heart rate. Should not be used to treat compensatory hypertension (arteriovenous shunt or coarctation of aorta).

Hydralazine (Apresoline)

Clinical Context:  Decreases systemic resistance through direct vasodilation of arterioles.

Class Summary

Used to treat hypertensive emergencies. Vasodilators reduce SVR, which, in turn, may allow forward flow, improving cardiac output.

Further Outpatient Care

Patients who have had acute poststreptococcal glomerulonephritis should be monitored according to the following schedule:

Further Inpatient Care

In the acute phase, admit for observation and treatment of hypertension and congestive heart failure.

Admit for monitoring and to initiate dialysis (when indicated) if renal function progressively worsens.

Inpatient & Outpatient Medications

In the acute phase, diuretics may be needed to control edema and congestive heart failure. Most patients do not require any medications after the acute phase, but antihypertensives may be needed in the chronic phase if the patient's blood pressure remains high.

Transfer

Transfer may be necessary if renal biopsy facilities are not available and the diagnosis is in doubt or if rapidly progressive renal failure develops.

Transfer may be necessary if azotemia worsens and dialysis facilities are not available on site.

Deterrence/Prevention

Preventive measures are as follows:

Complications

Complications in the acute phase include the following:

Complications in the chronic phase include the following:

Prognosis

In children, the immediate prognosis is excellent.[4] In elderly patients who have congestive heart failure or azotemia in the early phase, early mortality rates can be as high as 25%.

The long-term prognosis is debatable. Fewer than 1% of children have elevated serum creatinine values after 10-15 years of follow-up. Adults who develop massive proteinuria often have the garlandlike pattern of immune deposits. Their prognosis is worse; approximately 25% progress to chronic renal failure.

Patient Education

See the list below:

What is poststreptococcal glomerulonephritis?What is the pathophysiology of poststreptococcal glomerulonephritis?What is the prevalence of poststreptococcal glomerulonephritis in the US?What is the global prevalence of poststreptococcal glomerulonephritis?What is the mortality and morbidity associated with poststreptococcal glomerulonephritis?What are the racial predilections of poststreptococcal glomerulonephritis?What are the sexual predilections of poststreptococcal glomerulonephritis?Which age groups have the highest prevalence of poststreptococcal glomerulonephritis?Which clinical history findings are characteristic of poststreptococcal glomerulonephritis?What are the signs and symptoms of complicated acute poststreptococcal glomerulonephritis (APSGN)?Which physical findings are characteristic of poststreptococcal glomerulonephritis?What are the signs and symptoms of edema in poststreptococcal glomerulonephritis?Which physical findings are characteristic of hypertension in poststreptococcal glomerulonephritis?What causes hypertension in poststreptococcal glomerulonephritis?How prevalent is hypertensive encephalopathy in poststreptococcal glomerulonephritis?What are the signs and symptoms of oliguria in poststreptococcal glomerulonephritis?What are the possible cardiovascular findings in poststreptococcal glomerulonephritis?What is the prevalence of pulmonary hemorrhage in poststreptococcal glomerulonephritis?What causes poststreptococcal glomerulonephritis?Which conditions are included in the differential diagnoses of poststreptococcal glomerulonephritis?What are the differential diagnoses for Poststreptococcal Glomerulonephritis?What is the role of lab tests in the workup of poststreptococcal glomerulonephritis?What is the role of renal function studies in the workup of poststreptococcal glomerulonephritis?Which serologic findings are characteristic of poststreptococcal glomerulonephritis?Which urinalysis findings are characteristic of poststreptococcal glomerulonephritis?What is the role of NT-proBNP measurement in the workup of poststreptococcal glomerulonephritis?Which imaging studies are characteristic of poststreptococcal glomerulonephritis?Which pathologic findings are characteristic of poststreptococcal glomerulonephritis?Which light microscopy findings are characteristic of poststreptococcal glomerulonephritis?Which immunofluorescence findings are characteristic of poststreptococcal glomerulonephritis?Which electron microscopy findings are characteristic of poststreptococcal glomerulonephritis?When is renal biopsy indicated in the workup of acute poststreptococcal glomerulonephritis (APSGN)?How is poststreptococcal glomerulonephritis treatment?What is the role of renal biopsy in the treatment of poststreptococcal glomerulonephritis?What is the role of throat cultures in the treatment of poststreptococcal glomerulonephritis?How are skin infections treated in poststreptococcal glomerulonephritis?When is empirical prophylactic treatment for poststreptococcal glomerulonephritis indicated?Which specialist consultations are beneficial to patients with poststreptococcal glomerulonephritis?Which dietary and activity modifications are used in the treatment of poststreptococcal glomerulonephritis?What is the role of medications in the treatment of poststreptococcal glomerulonephritis?Which medications in the drug class Vasodilators are used in the treatment of Poststreptococcal Glomerulonephritis?Which medications in the drug class Angiotensin-converting enzyme inhibitors are used in the treatment of Poststreptococcal Glomerulonephritis?Which medications in the drug class Calcium channel blockers are used in the treatment of Poststreptococcal Glomerulonephritis?Which medications in the drug class Diuretics are used in the treatment of Poststreptococcal Glomerulonephritis?What is included in the long-term monitoring of poststreptococcal glomerulonephritis?What is included in inpatient care of poststreptococcal glomerulonephritis?Which medications are used in the treatment of poststreptococcal glomerulonephritis?When is patient transfer indicated for the treatment of poststreptococcal glomerulonephritis?How is poststreptococcal glomerulonephritis prevented?What are the possible complications of acute poststreptococcal glomerulonephritis?What are the possible complications of chronic poststreptococcal glomerulonephritis?What is the prognosis of poststreptococcal glomerulonephritis?What is included in patient education about poststreptococcal glomerulonephritis?

Author

Duvuru Geetha, MD, MRCP, Assistant Professor of Medicine, Department of Renal Medicine, Bayview Medical Center, Johns Hopkins University School of Medicine

Disclosure: Received honoraria from Genentech for educational training of sales force for: Consultant to ChemoCentryx and Consultant to Kyowa Hakko Kirin.

Specialty Editors

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Ajay K Singh, MB, MRCP, MBA, Associate Professor of Medicine, Harvard Medical School; Director of Dialysis, Renal Division, Brigham and Women's Hospital; Director, Brigham/Falkner Dialysis Unit, Faulkner Hospital

Disclosure: Nothing to disclose.

Chief Editor

Vecihi Batuman, MD, FASN, Huberwald Professor of Medicine, Section of Nephrology-Hypertension, Tulane University School of Medicine; Chief, Renal Section, Southeast Louisiana Veterans Health Care System

Disclosure: Nothing to disclose.

Additional Contributors

Chike Magnus Nzerue, MD, FACP, Professor of Medicine, Associate Dean for Clinical Affairs, Meharry Medical College

Disclosure: Nothing to disclose.

References

  1. Balasubramanian R, Marks SD. Post-infectious glomerulonephritis. Paediatr Int Child Health. 2017 Sep 11. 1-8. [View Abstract]
  2. Maness DL, Martin M, Mitchell G. Poststreptococcal Illness: Recognition and Management. Am Fam Physician. 2018 Apr 15. 97 (8):517-522. [View Abstract]
  3. Zegers RH, Weigl A, Steptoe A. The death of Wolfgang Amadeus Mozart: an epidemiologic perspective. Ann Intern Med. 2009 Aug 18. 151(4):274-8, W96-7. [View Abstract]
  4. Rodriguez-Iturbe B, Musser JM. The current state of poststreptococcal glomerulonephritis. J Am Soc Nephrol. 2008 Oct. 19(10):1855-64. [View Abstract]
  5. Ahn SY, Ingulli E. Acute poststreptococcal glomerulonephritis: an update. Curr Opin Pediatr. 2008 Apr. 20(2):157-62. [View Abstract]
  6. Stamatiades EG, Tremblay ME, Bohm M, Crozet L, Bisht K, Kao D, et al. Immune Monitoring of Trans-endothelial Transport by Kidney-Resident Macrophages. Cell. 2016 Aug 11. 166 (4):991-1003. [View Abstract]
  7. Batsford SR, Mezzano S, Mihatsch M, et al. Is the nephritogenic antigen in post-streptococcal glomerulonephritis pyrogenic exotoxin B (SPE B) or GAPDH?. Kidney Int. 2005 Sep. 68(3):1120-9. [View Abstract]
  8. Oda T, Yoshizawa N, Yamakami K, Sakurai Y, Takechi H, Yamamoto K, et al. The role of nephritis-associated plasmin receptor (NAPlr) in glomerulonephritis associated with streptococcal infection. J Biomed Biotechnol. 2012. 2012:417675. [View Abstract]
  9. Bakr A, Mahmoud LA, Al-Chenawi F, et al. HLA-DRB1* alleles in Egyptian children with post-streptococcal acute glomerulonephritis. Pediatr Nephrol. 2007 Mar. 22(3):376-9. [View Abstract]
  10. Ilyas M, Tolaymat A. Changing epidemiology of acute post-streptococcal glomerulonephritis in Northeast Florida: a comparative study. Pediatr Nephrol. 2008 Jul. 23(7):1101-6. [View Abstract]
  11. Jackson SJ, Steer AC, Campbell H. Systematic Review: Estimation of global burden of non-suppurative sequelae of upper respiratory tract infection: rheumatic fever and post-streptococcal glomerulonephritis. Trop Med Int Health. 2011 Jan. 16(1):2-11. [View Abstract]
  12. Rodriguez-Iturbe B, Musser JM. The current state of poststreptococcal glomerulonephritis. J Am Soc Nephrol. 2008 Oct. 19(10):1855-64. [View Abstract]
  13. Hoy WE, White AV, Dowling A, Sharma SK, Bloomfield H, Tipiloura BT, et al. Post-streptococcal glomerulonephritis is a strong risk factor for chronic kidney disease in later life. Kidney International. May 2012. 81(10):1026-32. [View Abstract]
  14. VanDeVoorde RG 3rd. Acute poststreptococcal glomerulonephritis: the most common acute glomerulonephritis. Pediatr Rev. 2015 Jan. 36 (1):3-12; quiz 13. [View Abstract]
  15. Kakajiwala A, Bhatti T, Kaplan BS, Ruebner RL, Copelovitch L. Post-streptococcal glomerulonephritis associated with atypical hemolytic uremic syndrome: to treat or not to treat with eculizumab?. Clin Kidney J. 2016 Feb. 9 (1):90-6. [View Abstract]
  16. Mara-Koosham G, Stoltze K, Aday J, Rendon P. Pulmonary Renal Syndrome After Streptococcal Pharyngitis: A Case Report. J Investig Med High Impact Case Rep. 2016 Apr-Jun. 4 (2):2324709616646127. [View Abstract]
  17. Adikari M, Priyangika D, Marasingha I, Thamotheram S, Premawansa G. Post-streptococcal glomerulonephritis leading to posterior reversible encephalopathy syndrome: a case report. BMC Res Notes. 2014 Sep 13. 7:644. [View Abstract]
  18. Zaki SA, Shanbag P. Unusual presentation of poststreptococcal glomerulonephritis as posterior reversible encephalopathy syndrome. J Pediatr Neurosci. 2014 Jan. 9 (1):42-4. [View Abstract]
  19. Ayoob RM, Schwaderer AL. Acute Kidney Injury and Atypical Features during Pediatric Poststreptococcal Glomerulonephritis. Int J Nephrol. 2016. 2016:5163065. [View Abstract]
  20. Parra G, Rodriguez-Iturbe B, Batsford S, et al. Antibody to streptococcal zymogen in the serum of patients with acute glomerulonephritis: a multicentric study. Kidney Int. 1998 Aug. 54(2):509-17. [View Abstract]
  21. Glassock RJ, Alvarado A, Prosek J, Hebert C, Parikh S, Satoskar A, et al. Staphylococcus-related glomerulonephritis and poststreptococcal glomerulonephritis: why defining "post" is important in understanding and treating infection-related glomerulonephritis. Am J Kidney Dis. 2015 Jun. 65 (6):826-32. [View Abstract]
  22. Nadasdy T, Hebert LA. Infection-related glomerulonephritis: understanding mechanisms. Semin Nephrol. 2011 Jul. 31 (4):369-75. [View Abstract]
  23. Taskesen M, Taskesen T, Katar S, et al. Elevated plasma levels of N-terminal pro-brain natriuretic peptide in children with acute poststreptococcal glomerulonephritis. Tohoku J Exp Med. 2009 Apr. 217(4):295-8. [View Abstract]
  24. Wu SH, Liao PY, Yin PL, Zhang YM, Dong L. Elevated expressions of 15-lipoxygenase and lipoxin A4 in children with acute poststreptococcal glomerulonephritis. Am J Pathol. 2009 Jan. 174(1):115-22. [View Abstract]
  25. Sorger K, Gessler U, Hubner FK, et al. Subtypes of acute postinfectious glomerulonephritis. Synopsis of clinical and pathological features. Clin Nephrol. 1982 Mar. 17(3):114-28. [View Abstract]

Kidney biopsy from a 7-year-old child with acute poststreptococcal glomerulonephritis. Periodic acid–Schiff stain (at 40x) shows the intracapillary and occasional mesangial neutrophil (arrows). Courtesy of Laura Kidd, MD, Pathology and Laboratory Medicine, Tulane University Medical School.

Kidney biopsy from a 7-year-old child with acute poststreptococcal glomerulonephritis. Immunofluorescence (C3) shows a granular capillary and mesangial staining pattern with segmental areas of “lumpy-bumpy” staining (white arrows). Courtesy of Laura Kidd, MD, Pathology and Laboratory Medicine, Tulane University Medical School.

Kidney biopsy from a 7-year-old child with acute poststreptococcal glomerulonephritis. Electron microscopy image shows rare large subepithelial deposits, or “humps” (arrows). Courtesy of Laura Kidd, MD, Pathology and Laboratory Medicine, Tulane University Medical School.

Kidney biopsy from a 7-year-old child with acute poststreptococcal glomerulonephritis. Periodic acid–Schiff stain (at 40x) shows the intracapillary and occasional mesangial neutrophil (arrows). Courtesy of Laura Kidd, MD, Pathology and Laboratory Medicine, Tulane University Medical School.

Kidney biopsy from a 7-year-old child with acute poststreptococcal glomerulonephritis. Periodic acid–Schiff stain (at 40x) shows the intracapillary and occasional mesangial neutrophil (arrows). Courtesy of Laura Kidd, MD, Pathology and Laboratory Medicine, Tulane University Medical School.

Kidney biopsy from a 7-year-old child with acute poststreptococcal glomerulonephritis. Electron microscopy image shows rare large subepithelial deposits, or “humps” (arrows). Courtesy of Laura Kidd, MD, Pathology and Laboratory Medicine, Tulane University Medical School.

Kidney biopsy from a 7-year-old child with acute poststreptococcal glomerulonephritis. Electron microscopy image shows rare large subepithelial deposits, or “humps” (arrows). Courtesy of Laura Kidd, MD, Pathology and Laboratory Medicine, Tulane University Medical School.

Kidney biopsy from a 7-year-old child with acute poststreptococcal glomerulonephritis. Immunofluorescence (C3) shows a granular capillary and mesangial staining pattern with segmental areas of “lumpy-bumpy” staining (white arrows). Courtesy of Laura Kidd, MD, Pathology and Laboratory Medicine, Tulane University Medical School.